Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Mar 30.

Published in final edited form as: Eur Urol. 2011 May 25;60(5):964–971. doi: 10.1016/j.eururo.2011.05.032

Table 6. Analysis of preoperative characteristics for risk of overall complications for patients receiving presurgical targeted therapy prior to cytoreductive nephrectomy.

Characteristic	Univariable		Multivariate
	OR (95% CI)	p value	OR (95% CI)	p value
	Decline in serum albumin^*	4.3 (1.3–14.1)	0.015	4.20 (1.3–14.1)	0.021
BMI ≥30^*	3.8 (1.1–13.0)	0.031	2.35 (0.6–8.9)	0.208
Clinical T3 or T4^*	2.7 (0.9–7.4)	0.063	1.74 (0.5–5.5)	0.352
ECOG ≥2^*	3.5 (0.4–30.5)	0.265	2.59 (0.3–26.2)	0.420
Charlson ≥8	1.3 (0.4–4.0)	0.633	–	–
Received bevacizumab	1.4 (0.5–4.1)	0.515	–	–

OR = odds ratio; CI = confidence interval; BMI = body mass index; ECOG = Eastern Cooperative Oncology Group.

^*

Included in multivariate analysis.